Light-triggered, efficient cytosolic release of IM7-saporin targeting the putative cancer stem cell marker CD44 by photochemical internalization

Molecular Pharmaceutics

Volumn 11, Issue 8, 2014, Pages 2764-2776

  Bostad, Monica ^a   Kausberg, Marianne ^a   Weyergang, Anette ^a   Olsen, Cathrine Elisabeth ^a   Berg, Kristian ^a   Høgset, Anders ^a,b   Selbo, Pål Kristian ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b PCI Biotech AS   (Norway)

Author keywords

cancer stem cells; CD44; immunotoxin; photochemical internalization; photodynamic therapy

Indexed keywords

BIOTIN; CELL MARKER; FLUORESCENT DYE; HERMES ANTIGEN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; PHOTOSENSITIZING AGENT; REACTIVE OXYGEN METABOLITE; RIBOSOME INACTIVATING PROTEIN; SAPORIN; STREPTAVIDIN; DRUG CARRIER; RIBOSOME INACTIVATING PROTEIN 1;

ARTICLE; CANCER CELL LINE; CANCER STEM CELL; CELL MEMBRANE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; ENDOSOME; EPIFLUORESCENCE MICROSCOPY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ILLUMINATION; LIGHT EXPOSURE; LNCAP CELL LINE; LYSOSOME; MEMBRANE RUPTURE; MTT ASSAY; PHOTOCHEMICAL INTERNALIZATION; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL; CHEMISTRY; DRUG EFFECTS; LIGHT; METABOLISM; PHOTOCHEMOTHERAPY; PROCEDURES; SENSITIVITY AND SPECIFICITY; TIME; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; BIOTIN; CELL LINE, TUMOR; CYTOSOL; DRUG CARRIERS; ENDOSOMES; FLOW CYTOMETRY; HUMANS; IMMUNOTOXINS; LIGHT; LYSOSOMES; NEOPLASTIC STEM CELLS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; REACTIVE OXYGEN SPECIES; RIBOSOME INACTIVATING PROTEINS, TYPE 1; SENSITIVITY AND SPECIFICITY; STREPTAVIDIN; TIME FACTORS;

EID: 84905485900     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500129t     Document Type: Article

References (86)

1. Medema, J. P. Cancer stem cells: the challenges ahead Nat. Cell Biol. 2013, 15 (4) 338-344
2. Schepers, A. G.; Snippert, H. J.; Stange, D. E.; van den, B. M.; van Es, J. H.; van de, W. M.; Clevers, H. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas Science 2012, 337 (6095) 730-735
3. Chen, J.; Li, Y.; Yu, T. S.; McKay, R. M.; Burns, D. K.; Kernie, S. G.; Parada, L. F. A restricted cell population propagates glioblastoma growth after chemotherapy Nature 2012, 488 (7412) 522-526
4. Driessens, G.; Beck, B.; Caauwe, A.; Simons, B. D.; Blanpain, C. Defining the mode of tumour growth by clonal analysis Nature 2012, 488 (7412) 527-530
5. Maitland, N. J.; Collins, A. T. Prostate cancer stem cells: a new target for therapy J. Clin. Oncol. 2008, 26 (17) 2862-2870
6. Liu, C.; Kelnar, K.; Liu, B.; Chen, X.; Calhoun-Davis, T.; Li, H.; Patrawala, L.; Yan, H.; Jeter, C.; Honorio, S.; Wiggins, J. F.; Bader, A. G.; Fagin, R.; Brown, D.; Tang, D. G. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44 Nat. Med. 2011, 17 (2) 211-215
7. Dalerba, P.; Dylla, S. J.; Park, I. K.; Liu, R.; Wang, X.; Cho, R. W.; Hoey, T.; Gurney, A.; Huang, E. H.; Simeone, D. M.; Shelton, A. A.; Parmiani, G.; Castelli, C.; Clarke, M. F. Phenotypic characterization of human colorectal cancer stem cells Proc. Natl. Acad. Sci. U.S.A. 2007, 104 (24) 10158-10163
8. Fillmore, C. M.; Kuperwasser, C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy Breast Cancer Res. 2008, 10 (2) R25
9. Phillips, T. M.; McBride, W. H.; Pajonk, F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation J. Natl. Cancer Inst. 2006, 20 (24) 1777-1785
10. Hwang, W. L.; Yang, M. H.; Tsai, M. L.; Lan, H. Y.; Su, S. H.; Chang, S. C.; Teng, H. W.; Yang, S. H.; Lan, Y. T.; Chiou, S. H.; Wang, H. W. SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells Gastroenterology 2011, 141 (1) 279-291
11. Dallas, N. A.; Xia, L.; Fan, F.; Gray, M. J.; Gaur, P.; van, B. G.; Samuel, S.; Kim, M. P.; Lim, S. J.; Ellis, L. M. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition Cancer Res. 2009, 69 (5) 1951-1957
12. Dylla, S. J.; Beviglia, L.; Park, I. K.; Chartier, C.; Raval, J.; Ngan, L.; Pickell, K.; Aguilar, J.; Lazetic, S.; Smith-Berdan, S.; Clarke, M. F.; Hoey, T.; Lewicki, J.; Gurney, A. L. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy PLoS One 2008, 3 (6) e2428
13. Lee, C. J.; Dosch, J.; Simeone, D. M. Pancreatic cancer stem cells J. Clin. Oncol. 2008, 26 (17) 2806-2812
14. Chang, L.; Graham, P. H.; Hao, J.; Ni, J.; Bucci, J.; Cozzi, P. J.; Kearsley, J. H.; Li, Y. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance Cell Death. Dis. 2013, 10.1038/cddis.2013.407
15. Hao, J.; Madigan, M. C.; Khatri, A.; Power, C. A.; Hung, T. T.; Beretov, J.; Chang, L.; Xiao, W.; Cozzi, P. J.; Graham, P. H.; Kearsley, J. H.; Li, Y. In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147 PLoS One 2012, 7 (8) e40716
16. Negi, L. M.; Talegaonkar, S.; Jaggi, M.; Ahmad, F. J.; Iqbal, Z.; Khar, R. K. Role of CD44 in tumour progression and strategies for targeting J. Drug Targeting 2012, 20 (7) 561-573
17. Sironen, R. K.; Tammi, M.; Tammi, R.; Auvinen, P. K.; Anttila, M.; Kosma, V. M. Hyaluronan in human malignancies Exp. Cell Res. 2011, 317 (4) 383-391
18. Marhaba, R.; Zoller, M. CD44 in cancer progression: adhesion, migration and growth regulation J. Mol. Histol. 2004, 35 (3) 211-231
19. Toole, B. P.; Zoltan-Jones, A.; Misra, S.; Ghatak, S. Hyaluronan: a critical component of epithelial-mesenchymal and epithelial-carcinoma transitions Cells Tissues Organs 2005, 179 (1-2) 66-72
20. Pessac, B.; Defendi, V. Cell aggregation: role of acid mucopolysaccharides Science 1972, 175 (4024) 898-900
21. Peck, D.; Isacke, C. M. CD44 phosphorylation regulates melanoma cell and fibroblast migration on, but not attachment to, a hyaluronan substratum Curr. Biol. 1996, 6 (7) 884-890
22. DeGrendele, H. C.; Kosfiszer, M.; Estess, P.; Siegelman, M. H. CD44 activation and associated primary adhesion is inducible via T cell receptor stimulation J. Immunol. 1997, 159 (6) 2549-2553
23. Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 2012, 380 (9859) 2095-2128
24. Nikitin, A. Y.; Matoso, A.; Roy-Burman, P. Prostate stem cells and cancer Histol. Histopathol. 2007, 22 (9) 1043-1049
25. Tang, D. G.; Patrawala, L.; Calhoun, T.; Bhatia, B.; Choy, G.; Schneider-Broussard, R.; Jeter, C. Prostate cancer stem/progenitor cells: identification, characterization, and implications Mol. Carcinog. 2007, 46 (1) 1-14
26. Lawson, D. A.; Witte, O. N. Stem cells in prostate cancer initiation and progression J. Clin. Invest. 2007, 117 (8) 2044-2050
27. Patrawala, L.; Calhoun, T.; Schneider-Broussard, R.; Li, H.; Bhatia, B.; Tang, S.; Reilly, J. G.; Chandra, D.; Zhou, J.; Claypool, K.; Coghlan, L.; Tang, D. G. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells Oncogene 2006, 25 (12) 1696-1708
28. Palapattu, G. S.; Wu, C.; Silvers, C. R.; Martin, H. B.; Williams, K.; Salamone, L.; Bushnell, T.; Huang, L. S.; Yang, Q.; Huang, J. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer Prostate 2009, 69 (7) 787-798
29. Bonkhoff, H.; Stein, U.; Remberger, K. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate Virchows Arch. A: Pathol. Anat. Histopathol. 1993, 423 (4) 291-294
30. Krijnen, J. L.; Janssen, P. J.; Ruizeveld de Winter, J. A.; van, K. H.; Schroder, F. H.; van der Kwast, T. H. Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 1993, 100 (5) 393-398
31. Huang, J.; Yao, J. L.; di SantAgnese, P. A.; Yang, Q.; Bourne, P. A.; Na, Y. Immunohistochemical characterization of neuroendocrine cells in prostate cancer Prostate 2006, 66 (13) 1399-1406
32. Huang, J.; Wu, C.; di SantAgnese, P. A.; Yao, J. L.; Cheng, L.; Na, Y. Function and molecular mechanisms of neuroendocrine cells in prostate cancer Anal. Quant. Cytol. Histol. 2007, 29 (3) 128-138
33. Yuan, T. C.; Veeramani, S.; Lin, M. F. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells Endocr.-Relat. Cancer 2007, 14 (3) 531-547
34. Amorino, G. P.; Parsons, S. J. Neuroendocrine cells in prostate cancer Crit Rev. Eukaryotic Gene Expression 2004, 14 (4) 287-300
35. Weyergang, A.; Selbo, P. K.; Berstad, M. E.; Bostad, M.; Berg, K. Photochemical internalization of tumor-targeted protein toxins Lasers Surg. Med. 2011, 43 (7) 721-733
36. Selbo, P. K.; Weyergang, A.; Hogset, A.; Norum, O. J.; Berstad, M. B.; Vikdal, M.; Berg, K. Photochemical internalization provides time- and space-controlled endolysosomal escape of therapeutic molecules J. Controlled Release 2010, 1) 2-12
37. Bostad, M.; Berg, K.; Hogset, A.; Skarpen, E.; Stenmark, H.; Selbo, P. K. Photochemical internalization (PCI) of immunotoxins targeting CD133 is specific and highly potent at femtomolar levels in cells with cancer stem cell properties J. Controlled Release 2013, 168 (3) 317-326
38. Stratford, E. W.; Bostad, M.; Castro, R.; Skarpen, E.; Berg, K.; Hogset, A.; Myklebost, O.; Selbo, P. K. Photochemical internalization of CD133-targeting immunotoxins efficiently depletes sarcoma cells with stem-like properties and reduces tumorigenicity Biochim. Biophys. Acta 2013, 1830 (8) 4235-4243
39. Agostinis, P.; Berg, K.; Cengel, K. A.; Foster, T. H.; Girotti, A. W.; Gollnick, S. O.; Hahn, S. M.; Hamblin, M. R.; Juzeniene, A.; Kessel, D.; Korbelik, M.; Moan, J.; Mroz, P.; Nowis, D.; Piette, J.; Wilson, B. C.; Golab, J. Photodynamic therapy of cancer: an update CA Cancer J. Clin. 2011, 61 (4) 250-281
40. Hogset, A.; Prasmickaite, L.; Selbo, P. K.; Hellum, M.; Engesaeter, B. O.; Bonsted, A.; Berg, K. Photochemical internalisation in drug and gene delivery Adv. Drug Delivery Rev. 2004, 56 (1) 95-115
41. Selbo, P. K.; Hogset, A.; Prasmickaite, L.; Berg, K. Photochemical internalisation: a novel drug delivery system Tumour Biol. 2002, 23 (2) 103-112
42. Berg, K.; Selbo, P. K.; Prasmickaite, L.; Tjelle, T. E.; Sandvig, K.; Moan, J.; Gaudernack, G.; Fodstad, O.; Kjolsrud, S.; Anholt, H.; Rodal, G. H.; Rodal, S. K.; Hogset, A. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol Cancer Res. 1999, 59 (6) 1180-1183
43. Prasmickaite, L.; Hogset, A.; Selbo, P. K.; Engesaeter, B. O.; Hellum, M.; Berg, K. Photochemical disruption of endocytic vesicles before delivery of drugs: a new strategy for cancer therapy Br. J. Cancer 2002, 86 (4) 652-657
44. An Open-label, Single Arm, Multi-centre Phase II Study to Evaluate Safety and Efficacy of PC-A11 in Patients With Recurrent Non-metastatic Head and Neck Squamous Cell Carcinoma Unsuitable for Surgery and Radiotherapy. ClinicalTrials; gov Identifier: NCT01606566; PCI Biotech AS: Oslo, Norway, 2012.
45. Phase I, Dose-escalating Study to Evaluate Safety and Tolerance of Amphinex Based Photochemical Internalisation (PCI) of Bleomycin in Patients With Local Recurrence or Advanced/Metastatic, Cutaneous or Sub-cutaneous Malignancies. ClinicalTrials; gov identifier: NCT00993512; PCI Biotech AS: Oslo, Norway, 2011.
46. Selbo, P. K.; Weyergang, A.; Eng, M. S.; Bostad, M.; Maelandsmo, G. M.; Hogset, A.; Berg, K. Strongly amphiphilic photosensitizers are not substrates of the cancer stem cell marker ABCG2 and provides specific and efficient light-triggered drug delivery of an EGFR-targeted cytotoxic drug J. Controlled Release 2012, 159 (2) 197-203
47. Stirpe, F. Ribosome-inactivating proteins Toxicon 2004, 44 (4) 371-383
48. Santanche, S.; Bellelli, A.; Brunori, M. The unusual stability of saporin, a candidate for the synthesis of immunotoxins Biochem. Biophys. Res. Commun. 1997, 234 (1) 129-132
49. Selbo, P. K.; Weyergang, A.; Bonsted, A.; Bown, S. G.; Berg, K. Photochemical internalization of therapeutic macromolecular agents: a novel strategy to kill multidrug-resistant cancer cells J. Pharmacol. Exp. Ther. 2006, 319 (2) 604-612
50. Polito, L.; Bortolotti, M.; Mercatelli, D.; Battelli, M. G.; Bolognesi, A. Saporin-S6: A useful tool in cancer therapy Toxins (Basel) 2013, 5 (10) 1698-1722
51. Fabian, A.; Barok, M.; Vereb, G.; Szollosi, J. Die hard: are cancer stem cells the Bruce Willises of tumor biology? Cytometry, Part A 2009, 75 (1) 67-74
52. Nagano, O.; Okazaki, S.; Saya, H. Redox regulation in stem-like cancer cells by CD44 variant isoforms Oncogene 2013, 32 (44) 5191-5198
53. Baumgartner, G.; Gomar-Hoss, C.; Sakr, L.; Ulsperger, E.; Wogritsch, C. The impact of extracellular matrix on the chemoresistance of solid tumors - experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy Cancer Lett. 1998, 131 (1) 85-99
54. Olsen, C. E.; Berg, K.; Selbo, P. K.; Weyergang, A. Circumvention of resistance to photodynamic therapy in doxorubicin-resistant sarcoma by photochemical internalization of gelonin Free Radical Biol. Med. 2013, 65 (C) 1300-1309
55. Pure, E.; Cuff, C. A. A crucial role for CD44 in inflammation Trends Mol. Med. 2001, 7 (5) 213-221
56. Teder, P.; Vandivier, R. W.; Jiang, D.; Liang, J.; Cohn, L.; Pure, E.; Henson, P. M.; Noble, P. W. Resolution of lung inflammation by CD44 Science 2002, 296 (5565) 155-158
57. Ghosh, S. C.; Neslihan, A. S.; Klostergaard, J. CD44: a validated target for improved delivery of cancer therapeutics Expert Opin. Ther. Targets 2012, 16 (7) 635-650
58. Thankamony, S. P.; Knudson, W. Acylation of CD44 and its association with lipid rafts are required for receptor and hyaluronan endocytosis J. Biol. Chem. 2006, 281 (45) 34601-34609
59. Almalik, A.; Karimi, S.; Ouasti, S.; Donno, R.; Wandrey, C.; Day, P. J.; Tirelli, N. Hyaluronic acid (HA) presentation as a tool to modulate and control the receptor-mediated uptake of HA-coated nanoparticles Biomaterials 2013, 34 (21) 5369-5380
60. Ouasti, S.; Kingham, P. J.; Terenghi, G.; Tirelli, N. The CD44/integrins interplay and the significance of receptor binding and re-presentation in the uptake of RGD-functionalized hyaluronic acid Biomaterials 2012, 33 (4) 1120-1134
61. Yoon, H. Y.; Koo, H.; Choi, K. Y.; Lee, S. J.; Kim, K.; Kwon, I. C.; Leary, J. F.; Park, K.; Yuk, S. H.; Park, J. H.; Choi, K. Tumor-targeting hyaluronic acid nanoparticles for photodynamic imaging and therapy Biomaterials 2012, 33 (15) 3980-3989
62. Luo, Y.; Prestwich, G. D. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate Bioconjugate Chem. 1999, 10 (5) 755-763
63. Luo, Y.; Ziebell, M. R.; Prestwich, G. D. A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells Biomacromolecules 2000, 1 (2) 208-218
64. Coradini, D.; Zorzet, S.; Rossin, R.; Scarlata, I.; Pellizzaro, C.; Turrin, C.; Bello, M.; Cantoni, S.; Speranza, A.; Sava, G.; Mazzi, U.; Perbellini, A. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But Clin. Cancer Res. 2004, 10 (14) 4822-4830
65. Sugahara, S.; Okuno, S.; Yano, T.; Hamana, H.; Inoue, K. Characteristics of tissue distribution of various polysaccharides as drug carriers: influences of molecular weight and anionic charge on tumor targeting Biol. Pharm. Bull. 2001, 24 (5) 535-543
66. Akima, K.; Ito, H.; Iwata, Y.; Matsuo, K.; Watari, N.; Yanagi, M.; Hagi, H.; Oshima, K.; Yagita, A.; Atomi, Y.; Tatekawa, I. Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity J. Drug Targeting 1996, 4 (1) 1-8
67. Tijink, B. M.; Buter, J.; de, B. R.; Giaccone, G.; Lang, M. S.; Staab, A.; Leemans, C. R.; van Dongen, G. A. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus Clin. Cancer Res. 2006, 12 (20 Pt 1) 6064-6072
68. Pelicano, H.; Carney, D.; Huang, P. ROS stress in cancer cells and therapeutic implications Drug Resist. Updates 2004, 7 (2) 97-110
69. Storz, P. Reactive oxygen species in tumor progression Front. Biosci. 2005, 10 (1881-96) 1881-1896
70. Pinthus, J. H.; Bryskin, I.; Trachtenberg, J.; Lu, J. P.; Singh, G.; Fridman, E.; Wilson, B. C. Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy Neoplasia 2007, 9 (1) 68-80
71. Husbeck, B.; Peehl, D. M.; Knox, S. J. Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing Free Radical Biol. Med. 2005, 38 (1) 50-57
72. Crow, P.; Barrass, B.; Kendall, C.; Hart-Prieto, M.; Wright, M.; Persad, R.; Stone, N. The use of Raman spectroscopy to differentiate between different prostatic adenocarcinoma cell lines Br. J. Cancer. 2005, 92 (12) 2166-2170
73. Ortel, B.; Sharlin, D.; ODonnell, D.; Sinha, A. K.; Maytin, E. V.; Hasan, T. Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells Br. J. Cancer. 2002, 87 (11) 1321-1327
74. Windahl, T.; Andersson, S. O.; Lofgren, L. Photodynamic therapy of localised prostatic cancer Lancet 1990, 336 (8723) 1139
75. Nathan, T. R.; Whitelaw, D. E.; Chang, S. C.; Lees, W. R.; Ripley, P. M.; Payne, H.; Jones, L.; Parkinson, M. C.; Emberton, M.; Gillams, A. R.; Mundy, A. R.; Bown, S. G. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study J. Urol. 2002, 168 (4 Pt 1) 1427-1432
76. Study of the Efficacy and Quality of Life after TOOKAD® Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Prostate Cancer. ClinicalTrials; gov Identifier: NCT01875393 13 A.D; Steba Biotech S.A: Luxemburg, 2014.
77. FitzGerald, D.; Pastan, I. Targeted toxin therapy for the treatment of cancer J. Natl. Cancer Inst. 1989, 81 (19) 1455-1463
78. Selbo, P. K.; Rosenblum, M. G.; Cheung, L. H.; Zhang, W.; Berg, K. Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel PLoS One 2009, 4 (8) e6691
79. Selbo, P. K.; Sivam, G.; Fodstad, O.; Sandvig, K.; Berg, K. In vivo documentation of photochemical internalization, a novel approach to site specific cancer therapy Int. J. Cancer. 2001, 92 (5) 761-766
80. Berg, K.; Folini, M.; Prasmickaite, L.; Selbo, P. K.; Bonsted, A.; Engesaeter, B. O.; Zaffaroni, N.; Weyergang, A.; Dietze, A.; Maelandsmo, G. M.; Wagner, E.; Norum, O. J.; Hogset, A. Photochemical internalization: a new tool for drug delivery Curr. Pharm. Biotechnol. 2007, 8 (6) 362-372
81. Tsoukas, M. M.; Lin, G. C.; Lee, M. S.; Anderson, R. R.; Kollias, N. Predictive dosimetry for threshold phototoxicity in photodynamic therapy on normal skin: red wavelengths produce more extensive damage than blue at equal threshold doses J. Invest. Dermatol. 1997, 108 (4) 501-505
82. Tang, C.; Ang, B. T.; Pervaiz, S. Cancer stem cell: target for anti-cancer therapy FASEB J. 2007, 21 (14) 3777-3785
83. Berg, K.; Berstad, M.; Prasmickaite, L.; Weyergang, A.; Selbo, P. K.; Hedfors, I.; Hogset, A. Photochemical internalization: a new tool for gene and oligonucleotide delivery Top. Curr. Chem. 2010, 296 (251-81) 251-281
84. Thong, P. S.; Ong, K. W.; Goh, N. S.; Kho, K. W.; Manivasager, V.; Bhuvaneswari, R.; Olivo, M.; Soo, K. C. Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma Lancet Oncol. 2007, 8 (10) 950-952
85. Berg, K.; Nordstrand, S.; Selbo, P. K.; Tran, D. T.; Angell-Petersen, E.; Hogset, A. Disulfonated tetraphenyl chlorin (TPCS2a), a novel photosensitizer developed for clinical utilization of photochemical internalization Photochem. Photobiol. Sci. 2011, 10 (10) 1637-1651
86. Lou, P. J.; Lai, P. S.; Shieh, M. J.; Macrobert, A. J.; Berg, K.; Bown, S. G. Reversal of doxorubicin resistance in breast cancer cells by photochemical internalization Int. J. Cancer. 2006, 119 (11) 2692-2698